Recommended

Teva close to API business sale
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

Novo Nordisk $11b acquisition to support manufacturing capacity

4
SHARES

As part of its acquisition of Catalent, Novo Holdings plans to sell three Catalent fill-finish sites, supporting the growth of the European and US manufacturing capacity.

Novo Nordisk and Catalent

Credit: ricochet64 / Shutterstock.com

Novo Nordisk is set to acquire three fill-finish manufacturing sites from Novo Holdings A/S (Novo Holdings) for $11 billion. This agreement is part of a transaction in which Novo Holdings agreed to acquire the contract development and manufacturing organisation (CDMO) Catalent.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The three manufacturing sites in Anagni in Italy, Brussels in Belgium and in Bloomington, Indiana in the US, specialise in the sterile filling of drugs. In total, the three sites employ over than 3,000 people and all have ongoing collaborations with Novo Nordisk. The facilities account for just a portion of the 50 total Catalent sites.

Increasing capacity

Acquisition of the three sites will enable the manufacturing capacity to be expanded at scale and speed. Novo Nordisk specified that the transaction is expected to support an incremental increase in the company’s filling capacity from 2026 and onwards.

Acquisition benefits for Novo Nordisk

“We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture and supply products that help people live better and healthier lives,” Kasim Kutay, CEO of Novo Holdings commented.

Lars Fruergaard Jørgensen, President and Chief Executive Officer at Novo Nordisk confirmed that operationally, the acquisition will “provide strategic flexibility” to the firm’s existing supply network.

Jørgensen shared that the firm is “very pleased” with the agreement, as it will allow the company to “serve significantly more people living with diabetes and obesity in the future”.

The merger of Catalent and the Novo Holdings subsidiary is anticipated to occur towards the end of 2024, upon completion of certain closing conditions. Acquisition of the fill-finish sites will be completed “as soon as possible”, according to Novo Nordisk.

The company also assured that until the acquisition is completed, Catalent will remain independent and separate from Novo Holdings and Novo Nordisk.

Continued manufacturing expansion

This news follows Novo Nordisk’s multi-billion dollar investment in November 2023, where the company announced plans to expand its production sites in France.

Share via
Share via